The second line may be the optimal setting for patients with HR+/HER2− advanced breast cancer to receive CDK4/6is, according to findings from the phase III SONIA trial presented at the 2023 ASCO Annual Meeting [61]. This evidence concerns the gene HR and breast carcinoma.